NASDAQ:VXRTVaxart Stock Price, Forecast & News

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VXRT shares have increased by 286.5% and is now trading at $8.00. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaxart.

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Vaxart.

Vaxart Inc (NASDAQ:VXRT) announced its earnings results on Tuesday, May, 12th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.02. The biotechnology company earned $2.90 million during the quarter, compared to the consensus estimate of $2.80 million. Vaxart had a negative return on equity of 94.20% and a negative net margin of 252.86%. View Vaxart's earnings history.

Vaxart's stock reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

2 brokers have issued 1-year target prices for Vaxart's stock. Their forecasts range from $6.00 to $7.00. On average, they anticipate Vaxart's share price to reach $6.50 in the next twelve months. This suggests that the stock has a possible downside of 18.8%. View analysts' price targets for Vaxart.

News articles about VXRT stock have trended very negative this week, InfoTrie reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Vaxart earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Vaxart.

Some companies that are related to Vaxart include Alector (ALEC), SpringWorks Therapeutics (SWTX), Bill.com (RVMD), Twist Bioscience (TWST), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Beam Therapeutics (BEAM), Regenxbio (RGNX), I-Mab (BDTX), Mesoblast (MESO), Cortexyme (CRTX), Adaptimmune Therapeutics (ADAP), Sorrento Therapeutics (SRNE), Coherus Biosciences (CHRS) and Passage Bio (PASG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), VBI Vaccines (VBIV), Conatus Pharmaceuticals (CNAT), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), Agile Therapeutics (AGRX) and Co-Diagnostics (CODX).

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VXRT stock can currently be purchased for approximately $8.00.

Vaxart has a market capitalization of $593.47 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 34 workers across the globe.

The official website for Vaxart is www.vaxart.com.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]